Given that ASS1 functions as the rate-limiting enzyme in the synthesis of arginine de novo, it is not only highly expressed in CRC but also directly associated with the proliferative activity and invasive capacity of tumor cells [21], providing a key node for precise intervention targeting CRC metabolism. The gene discussed is ASS1; the disease is colorectal carcinoma.